CONCORD — State Rep. Garrett Muscatel (D-Hanover) and State Sen. Dan Feltes (D-Concord) announced the filing of legislation to prohibit insurers from charging patients more than $100 for a 30-day supply of insulin.

Modeled after legislation recently signed into law in Colorado, the New Hampshire bill seeks to address dramatic price increases in recent years that have forced some diabetics to ration or forego taking insulin at significant risk to their health.

“Over seven million Americans rely on insulin to treat diabetes. While the cost of producing insulin has not changed, manufacturers have artificially skyrocketed the price in recent years to increase their profits. Diabetics need insulin to survive, and recent price spikes have forced many to ration or skip doses, often with tragic consequences. This legislation follows Colorado’s lead by preventing insurers from charging over $100 for a 30-day supply of insulin. While some drug manufacturers have talked about reducing the price of insulin in the future, those who need it don’t have time to wait. This legislation will save lives by ensuring that those who need insulin to survive are able to access it affordably,” said Muscatel.

“Every day, New Hampshire families are impacted by the absurdly high cost of insulin. Parents should never be forced to choose between the health of their child and their financial security,” said Feltes. “This legislation will give Granite Staters with diabetes the peace of mind they need and deserve by reducing the costs to obtain life-saving and life-sustaining insulin.”

Recommended for you

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.